Annals of Surgical Oncology

, Volume 23, Issue 11, pp 3609–3615

The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer

  • Matthew Susko
  • Jason Lee
  • Joseph Salama
  • Samantha Thomas
  • Hope Uronis
  • David Hsu
  • John Migaly
  • Christopher Willett
  • Brian Czito
  • Manisha Palta
Radiation Oncology

Abstract

Background

The optimal approach to patients with locally recurrent, non-metastatic rectal cancer is unclear. This study evaluates the outcomes and toxicity associated with pelvic re-irradiation.

Methods

Patients undergoing re-irradiation for locally recurrent, non-metastatic, rectal cancer between 2000 and 2014 were identified. Acute and late toxicities were assessed using common terminology criteria for adverse events version 4.0. Disease-related endpoints included palliation of local symptoms, surgical outcomes, and local progression-free survival (PFS), distant PFS and overall survival (OS) using the Kaplan–Meier method.

Results

Thirty-three patients met the criteria for inclusion in this study. Two (6 %) experienced early grade 3+ toxicity and seven (21 %) experienced late grade 3+ toxicity. Twenty-three patients presented with symptomatic local recurrence and 18 (78 %) reported symptomatic relief. Median local PFS was 8.7 (95 % CI 3.8–15.2) months, with a 2-year rate of 15.7 % (4.1–34.2), and median time to distant progression was 4.4 (2.2–33.3) months, with a 2-year distant PFS rate of 38.9 % (20.1–57.3). Median OS time for patients was 23.1 (11.1–33.0) months. Of the 14 patients who underwent surgery, median survival was 32.3 (13.8–48.0) months compared with 13.3 (2.2–33.0) months in patients not undergoing surgery (p = 0.10). A margin-negative (R0) resection was achieved in 10 (71 %) of the surgeries. Radiation treatment modality (intensity-modulated radiation therapy, three-dimensional conformal radiotherapy, intraoperative radiation therapy) did not influence local or distant PFS or OS.

Conclusion

Re-irradiation is a beneficial treatment modality for the management of locally recurrent, non-metastatic rectal cancer. It is associated with symptom improvement, low rates of toxicity, and similar benefits among radiation modalities.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13(4):245–52.CrossRefPubMedGoogle Scholar
  4. 4.
    SRC Trial Group. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980–7.CrossRefGoogle Scholar
  5. 5.
    Das P, Skibber JM, Rodriguez-Bigas MA, et al. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol. 2006;29(3):219–24.CrossRefGoogle Scholar
  6. 6.
    Yu TK, Bhosale PR, Crane CH, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71(4):1175–80.CrossRefPubMedGoogle Scholar
  7. 7.
    Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984;53(6):1354–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Lingareddy V, Ahmad NR, Mohiuddin M. Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 1997;38(4):785–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Bouchard PE, J. Management of recurrent rectal cancer. Ann Surg Oncol. 2010;17:1343–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64(4):1129–39.CrossRefPubMedGoogle Scholar
  11. 11.
    Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol. 2001;27(4):349–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Guiney MJ, Smith JG, Worotniuk V, Ngan S, Blakey D. Radiotherapy treatment for isolated loco-regional recurrence of rectosigmoid cancer following definitive surgery: Peter MacCallum Cancer Institute experience, 1981–1990. Int J Radiat Oncol Biol Phys. 1997;38(5):1019–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010;77(1):60–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Suzuki K, Gunderson LL, Devine RM, et al. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer. 1995;75(4):939–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer. 2002;95(5):1144–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA. 2000;284(8):1008–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22(10):1785–96.CrossRefPubMedGoogle Scholar
  18. 18.
    Koom WS, Choi Y, Shim SJ, et al. Reirradiation to the pelvis for recurrent rectal cancer. J Surg Oncol. 2012;105(7): 637–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Lindel K, Willett CG, Shellito PC, et al. Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer. Radiother Oncol. 2001;58(1):83–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Cai G, Zhu J, Hu W, Zhang Z. Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. Radiat Oncol. 2014;9:278.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Matthew Susko
    • 1
  • Jason Lee
    • 1
  • Joseph Salama
    • 1
  • Samantha Thomas
    • 1
  • Hope Uronis
    • 1
  • David Hsu
    • 1
  • John Migaly
    • 1
  • Christopher Willett
    • 1
  • Brian Czito
    • 1
  • Manisha Palta
    • 1
  1. 1.Department of Radiation OncologyDuke Cancer CenterDurhamUSA

Personalised recommendations